3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
6
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
Primary Myelofibrosis
1
Pancreatic Neoplasms
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia
1
Glioblastoma
1
Genital Neoplasms, Male
1
Genital Diseases, Male
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Castration-resistant Prostate Cancer
1
Carcinoma, Hepatocellular
1
Interventions
abiraterone
1
VT-464
1
Cyclophosphamide
1
Control Groups
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Castration-resistant Prostate Cancer
×
abiraterone
×
Clear all
NCT04839055
2021-04-09
CoA-CRPC
Jiangnan University
Phase 1/2
Unknown
50 enrolled